We are delighted to have been shortlisted for the European Mediscience Awards 2024!
🌟 Chief Executive of the Year Award
🌟 Best Communication Award
Learn more: https://t.co/GRP5DrUxSK
@EuromedEvent#HVO#MediScienceAwards#EMA24
Great news! 🙌 We are delighted to share that #HVO received the Best Central/Specialty Laboratory🔬🥼 Award at @vaccinenation The World Vaccine Congress 2024 ViE Awards.
Many congratulations to our fantastic Lab team at hVIVO for their dedication & hard work! 🚀
#wvc2024
We have been shortlisted for 2 categories for the ViE Awards hosted by @Terrapinn at the @vaccinenation#WVC in Washington:
✅Best Clinical Trial Company Award
✅Best Central/Specialty Laboratory Award
Voting is open until 16 Feb:
https://t.co/cV3aSzYP3I
#HVO#VIEAwards#WVC24
BIO-EUROPE is back & we are attending! 🚀 Our Directors of Business Development will be representing #HVO & @VennLifeScience at the 29th annual international partnering conference in Munich.
Our team look forward to meeting fellow industry colleagues there! 🤝
@EBDgroup
We opened our state-of-the-art @FluCamp screening facility to the local #Whitechapel community, to take part in a health check:
🩸 Blood pressure reading
💨Lung function
⚖️BMI
We look forward to incorporating further #ESG initiatives, stay tuned! 🚀
#HVO#BMI#HealthCheck
We recently reached a HUGE milestone 🎉!
Our team has successfully inoculated more than 4000 volunteers & conducted more than 70 Human Challenge Studies 🔬 Here’s to more ground-breaking achievements as we remain committed to leading the way in human challenge trials 🚀!
#HVO
Pretzel, Paul Thurk’s baby. Thank you Paul. He really wanted this to work, and so proud of this launch. Thank you Jay Parrish for picking up the ball and running.
We have signed a £10.4m contract with an existing top 5 global #pharmaceutical client to manufacture a new #influenza H1N1 strain #virus and conduct a human challenge trial to test the client’s #antiviral product.
Learn more: https://t.co/UgPc6oB5c9 #ORPH#hVIVO#FLU
Our #CEO & @KatiePilbeamTV @proactive_UK discuss this mornings results. They touch on the record year of 2021 & significant growth. Mo also discusses what to look forward to in 2022 continue as #ORPH continues its upward trajectory
Watch full #interview:
https://t.co/8dkjXT6cCE
We have been awarded a new study with an existing #BigPharma client to provide a #vaccination site for a Phase II field study for the client’s #RSV#vaccine candidate, @hVIVO's 1st study of this kind following the expansion of our facilities. #ORPH
https://t.co/hdy8brAqov